Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanical Properties of Percutaneous Transluminal Coronary Angioplasty Balloon Catheters: A Bench Study.

Annals of biomedical engineering·2026
Same author

Diagnosis and Treatment of Hypersensitivity Pneumonitis: S2k Guideline of the German Respiratory Society and the German Society for Allergology and Clinical Immunology.

Respiration; international review of thoracic diseases·2025
Same author

Design of percutaneous transluminal coronary angioplasty balloon catheters.

Biomedical engineering online·2023
Same author

[Linguistic Validation of the "German Lung Fibrosis Health Related Quality of Life Questionnaire"].

Pneumologie (Stuttgart, Germany)·2021
Same author

Transcriptomic analysis of the mouse retina after acute and chronic normobaric and hypobaric hypoxia.

Scientific reports·2021
Same author

Artificial intelligence solution to classify pulmonary nodules on CT.

Diagnostic and interventional imaging·2020
Same journal

Pneumologie (Stuttgart, Germany)·2026
Same journal

Aerosol therapy during noninvasive ventilation (NIV) and nasal high-flow therapy (HFT): current technology and consensus-based recommendations.

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Correction: Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Erratum: Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Information from Section E3 of the DGP regarding the G-BA Resolution].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[Acute lung failure].

Pneumologie (Stuttgart, Germany)·2026
Same journal

[The internet as a source of information for patients with sarcoidosis].

Pneumologie (Stuttgart, Germany)·2026
See all related articles

Related Experiment Video

Updated: Jun 9, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

[Interstitial lung diseases - historical development, current status, future prospects].

J Behr1, U Costabel

  • 1Medizinische Klinik und Poliklinik I, Schwerpunkt Pneumologie, Klinikum der Universität München, München. juergen.behr@med.unimuenchen.de

Pneumologie (Stuttgart, Germany)
|September 10, 2010
PubMed
Summary
This summary is machine-generated.

Diffuse parenchymal lung diseases, including sarcoidosis and lung fibrosis, present diverse inflammatory and fibrotic processes. Recent advances in gene technology and clinical trials offer hope for new targeted therapies for fibrotic lung diseases.

Related Experiment Videos

Last Updated: Jun 9, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Pulmonary Medicine
  • Pathophysiology
  • Medical Histopathology

Context:

  • Sarcoidosis and lung fibrosis, identified in the 19th century, represent a spectrum of diffuse parenchymal lung diseases.
  • These conditions manifest in the lung interstitium, ranging from inflammatory to purely fibrotic processes.
  • Effective anti-inflammatory treatments exist for inflammatory forms, but therapies for fibrotic lung disease remain limited.

Purpose:

  • To review the evolving understanding of fibrotic lung disease pathophysiology.
  • To highlight advancements in diagnostic tools like high-resolution computed tomography (HRCT).
  • To discuss recent therapeutic trial outcomes and future directions in treating fibrotic lung diseases.

Summary:

  • Diffuse parenchymal lung diseases encompass a range of inflammatory and fibrotic conditions affecting the lung interstitium.
  • Gene technology has significantly advanced the understanding of fibrotic lung disease pathophysiology.
  • Recent clinical trials for idiopathic pulmonary fibrosis (IPF) show promise for antioxidant therapies (N-acetylcysteine) and pirfenidone, demonstrating trial feasibility.

Impact:

  • Improved early and differential diagnosis of diffuse parenchymal lung diseases through HRCT.
  • Demonstrated feasibility of clinical trials in idiopathic pulmonary fibrosis patients.
  • Established a foundation for developing novel, targeted therapies for fibrotic lung diseases based on enhanced pathophysiological understanding.